AI Maverick Intel Inc. has entered into a significant agreement with HEAL Group Holdings Inc. that grants the company right of first refusal on certain healthcare technology assets. The arrangement, effective February 11, 2026, allows AI Maverick Intel to review and match third-party offers for specific HEAL assets or business units under specified conditions.
The agreement provides AI Maverick Intel with potential acquisition access across HEAL's portfolio of artificial intelligence-driven healthcare technology and services. HEAL Group operates in more than six countries, giving the agreement international scope and significance. In exchange for these rights, AI Maverick Intel will issue 120,000,000 common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million.
This arrangement will remain in place for three years unless terminated earlier by mutual agreement between the companies. The right of first refusal mechanism gives AI Maverick Intel a strategic advantage in potentially acquiring healthcare technology assets that align with its focus on artificial intelligence and emerging technology-enabled industries.
The importance of this development lies in the growing intersection of artificial intelligence and healthcare technology, a sector experiencing rapid transformation and investment. By securing these rights, AI Maverick Intel positions itself to potentially acquire valuable assets in a high-growth industry without immediate capital expenditure, instead using equity as consideration. This approach allows the company to preserve cash while maintaining acquisition flexibility.
For the healthcare technology industry, this agreement represents continued consolidation and strategic positioning as companies seek to leverage artificial intelligence capabilities. The right of first refusal arrangement provides AI Maverick Intel with valuable time to evaluate potential acquisitions while preventing competing bids from securing assets without giving the company an opportunity to match offers.
The financial implications of this arrangement include the dilution effect of issuing 120 million shares, though at a relatively low price per share. Investors should monitor how this strategic positioning translates into actual acquisitions and whether the potential healthcare technology assets align with AI Maverick Intel's stated focus on creating scalable growth opportunities and long-term shareholder value.
Additional information about AI Maverick Intel is available through the company's newsroom at http://ibn.fm/AIMV. The original announcement was distributed through TechMediaWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides various distribution services including access to wire solutions through InvestorWire and social media distribution to millions of followers.
